Edition:
United Kingdom

Hutchison China MediTech Ltd (HCM.OQ)

HCM.OQ on NASDAQ Stock Exchange Global Select Market

31.67USD
13 Jul 2018
Change (% chg)

-- (--)
Prev Close
$31.67
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
27,502
52-wk High
$42.00
52-wk Low
$21.80

Latest Key Developments (Source: Significant Developments)

Hutchison China Meditech says ‍underwriters elected to purchase an additional 1.5 mln ADSs
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Hutchison China Meditech Ltd :UNDERWRITERS HAVE ELECTED TO PURCHASE AN ADDITIONAL 1.5 MILLION ADSS AT OFFERING PRICE OF US$26.50 PER ADS.‍TOTAL GROSS PROCEEDS OF OFFERING IS APPROXIMATELY US$301.3 MILLION​.  Full Article

Chi-Med reports preliminary phase II data on fruquintinib combination
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Hutchison China Meditech Ltd :CHI-MED REPORTS PRELIMINARY PHASE II DATA ON FRUQUINTINIB COMBINATION IN FIRST-LINE LUNG CANCER.HUTCHISON CHINA MEDITECH LTD SAYS ‍PRELIMINARY RESULTS IN 17 EFFICACY EVALUABLE PATIENTS SHOWED AN ORR OF 76 PERCENT AND A DCR OF 100 PERCENT​.HUTCHISON CHINA MEDITECH LTD SAYS ‍PRELIMINARY DATA FROM PHASE II TRIAL DEMONSTRATED PROMISING EFFICACY AND AN ACCEPTABLE SAFETY PROFILE​.  Full Article

Hutchison China Meditech H1 group revenue up 27 pct to $104.5 mln
Tuesday, 2 Aug 2016 

Hutchison China Meditech Ltd : Says h1 group revenue up 27% to $104.5 million (h1 2015: $82.5m . Says h1 consolidated revenue up 27% to $104.5 million (h1 2015: $82.5m) .Sees fy 2016 consolidated revenue $190-205 million.  Full Article

Hutchison China, AstraZeneca amend savolitinib co-development agreement
Monday, 1 Aug 2016 

Hutchison China Meditech : Co and astrazeneca amend co-development agreement to accelerate savolitinib global development program; .Amendment provides that chi-med will contribute up to $50 million, spread primarily over three years.  Full Article

BRIEF-Hutchison China MediTech Says FY ‍Group Revenue Up 12 Pct

* ‍FY NET LOSS ATTRIBUTABLE TO CHI-MED $26.7 MILLION VERSUS NET PROFIT $11.7M​ Source text for Eikon: Further company coverage:

No consensus analysis data available.